<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225781</url>
  </required_header>
  <id_info>
    <org_study_id>SP-ECT</org_study_id>
    <nct_id>NCT03225781</nct_id>
  </id_info>
  <brief_title>Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer</brief_title>
  <official_title>A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IGEA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electrochemotherapy is a type of electroporation that allows the delivery of drugs to the
      cells through the local creation of pores in the cell membrane. The electric pulses can be
      applied directly to the neoplastic cells, allowing for the local concentration of a possible
      chemotherapeutic agent administered through the bloodstream. This technique does not use heat
      nor other thermal energies and it is performed using special needles/electrodes linked to a
      generator (&quot;porator&quot;).

      In this study this technique will be applied on unresectable pancreatic cancer, already
      submitted to neoadjuvant treatment and still unresectable, through laparotomy. Bleomycin will
      be the chemotherapeutic agent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>through study completion, 1 year</time_frame>
    <description>Number of adverse events related with electrochemotherapy (within 12 months after treatment) are registered and analyzed according to the CTCAE version 4.0. Complications are distinct in early (during hospitalization) and late (bile duct stenosis) that may appear during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>through study completion, 1 year</time_frame>
    <description>Number of procedures planned actually performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour response</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of effects of electrochemotherapy on tumor using RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of quality of life using the Karnovsky performance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of quality of life using the pain numeric scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival analysis through the calculation of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival analysis through the calculation of progression free survival survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunomonitoring</measure>
    <time_frame>From baseline to the first month</time_frame>
    <description>Study of adaptive immunity through the sampling of Interleukin6 and Heat shock protein 70 levels at baseline and post-procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrochemotherapy with Bleomycin</intervention_name>
    <description>Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiologic confirmation of locally advanced pancreatic cancer by at least contrast
             enhanced CT of chest and abdomen (with the upper abdomen scanned according to a
             dedicated 3mm slice multiphase pancreatic tumor protocol), performed maximum 4 weeks
             prior to the procedure

          -  Cytohistological diagnosis of pancreatic cancer

          -  Age &gt; 18 and &lt; 80

          -  Stable disease after chemotherapy (no tumor progression, no oncomarkers (Carbohydrate
             Antigen 19-9 [CA 19-9] or Carcinoembryonic antigen [CEA]) increase

          -  Performance Status 0 sec. ECOG (Eastern Cooperative Oncology Group)

          -  Written informed consent

        Exclusion Criteria:

          -  Resectable pancreatic cancer as assessed by multidisciplinary meeting

          -  Stage IV disease

          -  Patients receiving fenitoin, phosphofenitoin or living vaccines

          -  Pregnancy

          -  Progressive disease (either dimensional and not only by stage)

          -  &lt; 18 years old and &gt; 80
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Verona Hospital</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Paiella, MD</last_name>
      <phone>+390458126009</phone>
      <email>salvatore.paiella@aovr.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Paiella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Landoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Esposito, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Casetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Bassi, MD, FRCS, FACS, FEBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Granata V, Fusco R, Piccirillo M, Palaia R, Petrillo A, Lastoria S, Izzo F. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int J Surg. 2015 Jun;18:230-6. doi: 10.1016/j.ijsu.2015.04.055. Epub 2015 Apr 24.</citation>
    <PMID>25917204</PMID>
  </results_reference>
  <results_reference>
    <citation>Bimonte S, Leongito M, Granata V, Barbieri A, Del Vecchio V, Falco M, Nasto A, Albino V, Piccirillo M, Palaia R, Amore A, Giacomo Rd, Lastoria S, Setola SV, Fusco R, Petrillo A, Izzo F. Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies. Radiol Oncol. 2016 Feb 16;50(1):14-20. doi: 10.1515/raon-2016-0003. eCollection 2016 Mar 1. Review.</citation>
    <PMID>27069445</PMID>
  </results_reference>
  <results_reference>
    <citation>Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, Vecchiato A, Corti L, Rossi CR, Nitti D. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol. 2009 Jan;16(1):191-9. doi: 10.1245/s10434-008-0204-8. Epub 2008 Nov 6.</citation>
    <PMID>18987914</PMID>
  </results_reference>
  <results_reference>
    <citation>Girelli R, Prejan√≤ S, Cataldo I, Corbo V, Martini L, Scarpa A, Claudio B. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol. 2015 Mar 25;49(2):147-54. doi: 10.1515/raon-2015-0013. eCollection 2015 Jun.</citation>
    <PMID>26029026</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Salvatore Paiella, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

